The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
CCL2 is a Potent Regulator of Prostate Cancer Cell Migration and Proliferation
Open accessAbstract
Tumor cells in the bone interact with the microenvironment to promote tumor cell survival and proliferation, resulting in a lethal phenotype for patients with advanced prostate cancer. Monocyte chemoattractant protein 1 (CCL2) is a member of the CC chemokine family and is known to promote monocyte chemotaxis to sites of inflammation. Here we have shown that human bone marrow endothelial (HBME) cells secrete significantly higher levels of CCL2 compared to human aortic endothelial cells and human dermal microvascular endothelial cells. Furthermore, we demonstrate that CCL2 is a potent chemoattractant of prostate cancer epithelial cells, and that stimulation of PC-3 and VCaP cells resulted in a dose-dependent activation of PI3 kinase/Akt signaling pathway. Activation of the PI3 kinase/Akt pathway was found to be vital to the proliferative effects of CCL2 stimulation of both PC-3 and VCaP cells. Additionally, CCL2 stimulated the phosphorylation of p70-S6 kinase (a downstream target of Akt) and induced actin rearrangement, resulting in a dynamic morphologic change indicative of microspike formation. These data suggest that bone marrow endothelial cells are a major source of CCL2, and that an elevated secretion of CCL2 recruits prostate cancer epithelial cells to the bone microenvironment and regulates their proliferation rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
The activation of Akt/PKB signaling pathway and cell survival
Song, G., Ouyang, G., & Bao, S. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00337.x · Cited by 1,888
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Taichman, R. S., Cooper, C. R., Keller, E. T., Pienta, K. J., Taichman, N. S., & McCauley, L. K. (2002) · PubMed · Cited by 994
Self-citationAndrogen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., MacVicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2442 · Cited by 617
Self-citationOsteoblasts in prostate cancer metastasis to bone
Logothetis, C. J., & Lin, S.-H. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1528 · Cited by 614
Negus, R. P. M., Stamp, G. W. H., Hadley, J., & Balkwill, F. R. (1997) · Europe PMC (PubMed Central) · Cited by 339
Negus, R. P., Stamp, G. W., Relf, M. G., Burke, F., Malik, S. T., Bernasconi, S., Allavena, P., Sozzani, S., Mantovani, A., & Balkwill, F. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117933 · Cited by 315
Saji, H., Koike, M., Yamori, T., Saji, S., Seiki, M., Matsushima, K., & Toi, M. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5<1085::aid-cncr1424>3.0.co;2-k · Cited by 288
Balkwill, F. (2003) · Seminars in Immunology · doi:10.1016/s1044-5323(02)00127-6 · Cited by 236
The chemokine network in cancer - much more than directing cell movement
Kulbe, H., Levinson, N. R., Balkwill, F., & Wilson, J. L. (2004) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041814hk · Cited by 209
Ohta, M., Kitadai, Y., Tanaka, S., Yoshihara, M., Yasui, W., Mukaida, N., Haruma, K., & Chayama, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.10705 · Cited by 153
Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer
Valković, T., Lučin, K., Krstulja, M., Dobi-Babić, R., & Jonjić, N. (1998) · Pathology - Research and Practice · doi:10.1016/s0344-0338(98)80057-5 · Cited by 137
Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer
Lebrecht, A., Grimm, C., Lantzsch, T., Ludwig, E., Hefler, L., Ulbrich, E. J., & Koelbl, H. (2004) · Tumor Biology · doi:10.1159/000077718 · Cited by 131
Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis
Terashima, Y., Onai, N., Murai, M., Enomoto, M., Poonpiriya, V., Hamada, T., Motomura, K., Suwa, M., Ezaki, T., Haga, T., et al. (2005) · Nature Immunology · doi:10.1038/ni1222 · Cited by 117
Sauvonnet, N., Lambermont, I., van der Bruggen, P., & Cornelis, G. R. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03053.x · Cited by 92
Mazzucchelli, L., Loetscher, P., Каппелер, А., Uguccioni, M., Baggiolini, M., Laissue, J. A., & Mueller, C. (1996) · PubMed · Cited by 69
Raymond, C. R., Redman, S., & Crouch, M. F. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00500-0 · Cited by 61
Neumark, E., Sagi‐Assif, O., Shalmon, B., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11337 · Cited by 61
The “Emigration, Migration, and Immigration” of Prostate Cancer
Pienta, K. J., & Loberg, R. D. (2005) · Clinical Prostate Cancer · doi:10.3816/cgc.2005.n.008 · Cited by 57
Self-citationFlaishon, L., Becker-Herman, S., Hart, G., Levo, Y., Kuziel, W. A., & Shachar, I. (2004) · Blood · doi:10.1182/blood-2003-11-4013 · Cited by 49
Choi, E.-K., Park, H., Ma, J.-S., Lee, H., Kang, H., Kim, B.-G., & Kang, I. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00058-4 · Cited by 25
Moog-Lutz (1997) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0215(19970410)71:2
Cited by
More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis
Gschwandtner, M., Derler, R., & Midwood, K. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02759 · Cited by 611
Roca, H., Varsos, Z. S., Sud, S., Craig, M. J., Ying, C., & Pienta, K. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042671 · Cited by 569
Self-citationTargeting the CCL2-CCR2 signaling axis in cancer metastasis
Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N., & Muschel, R. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7376 · Cited by 501
Pienta, K. J., Machiels, J.-P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 412
Self-citationLoberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., Wojno, K., Snyder, L. A., Yan, L., & Pienta, K. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1286 · Cited by 333
Self-citation
Metadata
- Authors
- Loberg, R. D., Day, L. L., Harwood, J., Ying, C., St. John, L. N., Giles, R., Neeley, C. K., & Pienta, K. J.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2006-07
- Volume
- 8
- Issue
- 7
- Pages
- 578-586
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W2002535198
- Cited by
- 255
- References
- 26
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.